Follow
Serafin Morales
Serafin Morales
hospital arnau de vilanova de lleida
Verified email at gencat.cat
Title
Cited by
Cited by
Year
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6352017
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …
SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...
The Lancet Oncology 21 (4), 519-530, 2020
5772020
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga, X Carbonell, NJ Castañeda-Soto, M Clemens, M Green, ...
Journal of Clinical Oncology 23 (10), 2162-2171, 2005
5552005
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer …
A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ...
The lancet oncology 18 (4), 545-554, 2017
3202017
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 …
IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, ...
The lancet oncology 17 (6), 811-821, 2016
2892016
Pathogenesis of Salmonella enteritidis infection in laying chickens. I. Studies on egg transmission, clinical signs, fecal shedding, and serologic responses
HL Shivaprasad, JF Timoney, S Morales, B Lucio, RC Baker
Avian diseases, 548-557, 1990
2861990
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III …
V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ...
Journal of clinical oncology 21 (17), 3207-3213, 2003
2692003
Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
A Chan, B Moy, J Mansi, B Ejlertsen, FA Holmes, S Chia, H Iwata, ...
Clinical breast cancer 21 (1), 80-91. e7, 2021
1902021
Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas
G Moreno‐Bueno, F Salvador, A Martín, A Floristán, EP Cuevas, V Santos, ...
EMBO molecular medicine 3 (9), 528-544, 2011
1812011
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study
M Martín, S Loibl, G von Minckwitz, S Morales, N Martinez, A Guerrero, ...
Journal of Clinical Oncology 33 (9), 1045-1052, 2015
1622015
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with …
L Gianni, M Mansutti, A Anton, L Calvo, G Bisagni, B Bermejo, ...
JAMA oncology 4 (3), 302-308, 2018
1442018
Matrix vesicles produced by osteoblast-like cells in culture become significantly enriched in proteoglycan-degrading metalloproteinases after addition of β-glycerophosphate and …
DD Dean, Z Schwartz, L Bonewald, OE Muniz, S Morales, R Gomez, ...
Calcified tissue international 54, 399-408, 1994
1311994
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ...
JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020
1192020
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial
G von Minckwitz, M Colleoni, HC Kolberg, S Morales, P Santi, ...
The Lancet Oncology 19 (7), 987-998, 2018
982018
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant …
M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, ...
Annals of oncology 32 (4), 488-499, 2021
922021
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial
E Ciruelos, P Villagrasa, T Pascual, M Oliveira, S Pernas, L Paré, ...
Clinical Cancer Research 26 (22), 5820-5829, 2020
862020
Capivasertib in hormone receptor–positive advanced breast cancer
NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ...
New England Journal of Medicine 388 (22), 2058-2070, 2023
852023
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ...
Nature communications 11 (1), 385, 2020
792020
Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia
C Vadell, MA Seguí, JM Giménez-Arnau, S Morales, L Cirera, I Bestit, ...
American journal of clinical oncology 21 (4), 347-351, 1998
791998
Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI …
I Krop, S Johnston, IA Mayer, M Dickler, V Ganju, A Forero-Torres, ...
Cancer Research 75 (9_Supplement), S2-02-S2-02, 2015
722015
The system can't perform the operation now. Try again later.
Articles 1–20